NOK 2.66
(1.92%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -41.28 Million NOK | 57.17% |
2022 | -96.39 Million NOK | 64.46% |
2021 | -271.2 Million NOK | 5.94% |
2020 | -288.31 Million NOK | 0.0% |
2019 | - NOK | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -29.6 Thousand NOK | 3.04% |
2024 Q1 | -29.6 Thousand NOK | 99.93% |
2023 FY | -41.28 Million NOK | 57.17% |
2023 Q4 | -41.28 Million NOK | 0.0% |
2023 Q2 | -50.2 Million NOK | 0.0% |
2023 Q1 | - NOK | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Arctic Bioscience AS | -77.55 Million NOK | 46.767% |
Aqua Bio Technology ASA | -5.82 Million NOK | -608.279% |
ArcticZymes Technologies ASA | -237.27 Million NOK | 82.601% |
BerGenBio ASA | -155.55 Million NOK | 73.46% |
Hofseth BioCare ASA | 112.89 Million NOK | 136.567% |
PCI Biotech Holding ASA | -40.86 Million NOK | -1.028% |
Ultimovacs ASA | -262.84 Million NOK | 84.293% |